January 2022 Archives - Page 2 of 2 - FCS Hematology Oncology Review

Low Risk of Cardiovascular Events With ADT for Prostate Cancer; Higher Risk in Older Men

January 1, 2022

The risk of major adverse cardiovascular events (MACE) following the initiation of androgen deprivation therapy (ADT) in men with prostate cancer is higher for older men compared with their younger counterparts. However, the overall MACE risk at 1 year in all age groups starting ADT is 1% or less, which is much lower than previously published reports. The findings, gleaned from analyses of U.S. electronic medical records, were presented during the virtual National Comprehensive Cancer Network 2022 Annual Meeting.

Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial

January 1, 2022

Many of us have used platinum/paclitaxel in this setting but this study helps to corroborate the clinical practice.

Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108)

January 1, 2022

Benefit of locoregional control seems limited probably to situations in which surgery could clearly help recurrent breast inflammatory/infectious issues. This study is helpful to quote to patients who are anxious about not having breast surgery accomplished in this setting.

Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update

January 1, 2022

Role adjuvant chemotherapy in this setting will change significantly with incorporation of MRD evaluation post-surgery with prospective validation.

Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP

January 1, 2022

Interesting and common scenario in clinic. Self-reported symptoms do exist but delaying disease-progression may have salutary benefits in the long haul insofar as using dual androgen-deprivation therapy.

Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212)

January 1, 2022

PFS difference is small. But argument can be made for a younger patient who desires aggressive therapy and toxicities have been manageable.

Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia. NEJM Jan 2022

January 1, 2022

A single-group, phase 1–2 study indicated that eltrombopag improved the efficacy of standard immunosuppressive therapy that entailed horse antithymocyte globulin (ATG) plus cyclosporine in patients with severe aplastic anemia.

Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer

January 1, 2022

Another win for combined target-IO Rx with meaningful OS difference and reasonable/expected tolerability.

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

January 1, 2022

Incredible development for a small population of patients with uveal melanoma but nonetheless a new standard of care. Initial infusions may be complex in terms of close monitoring, as inpatient, till more experience is acquired in community oncology practices.

Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer

January 1, 2022

Interesting and encouraging development in this setting. The science and applicability of this drug in the scenario of no/low HER-2 expression will be thought-provoking. Interstitial pneumonitis is a concern.

Article Search

Low Risk of Cardiovascular Events With ADT for Prostate Cancer; Higher Risk in Older Men

Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial

Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108)

Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update

Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP

Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212)

Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia. NEJM Jan 2022

Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer

Keyword Search

Article Search

Cancer Types

Month Contributed

Show FCS Articles Only

Sort Order

Number of Posts

Menu

About This Site